Clinical Impact of Pharmacogenomic Screening on Warfarin Dosing Accuracy

Abstract

Warfarin's therapeutic index is narrow and its dose requirement varies five- to ten-fold across patients, a variability substantially explained by common variants in CYP2C9, VKORC1, and CYP4F2 -- genes that together shape both how quickly the drug is cleared and how sensitive its molecular target is to inhibition. This article synthesizes the literature on translating that genetic knowledge into clinical dosing practice: the discovery and mechanism of the causal variants; the pharmacogenetic dosing algorithms, most notably from the International Warfarin Pharmacogenetics Consortium, that combine genotype with clinical variables to predict a stable therapeutic dose; and the randomized controlled trials -- EU-PACT, COAG, and GIFT -- that tested whether genotype-guided dosing changes real anticoagulation control and clinical outcomes rather than just predicted dose. The trial evidence, read together with subsequent meta-analyses, supports a specific and appropriately modest conclusion: genotype-guided dosing reliably improves time in therapeutic range and reduces markedly supratherapeutic INR values, with a clinical-event benefit demonstrated in a surgical population, but the benefit is not uniform. The COAG trial's pre-specified subgroup analysis found that genotype-guided dosing performed significantly worse than clinical-algorithm dosing in African-American participants, a result traced to the two-allele CYP2C9 panel used in major trials being a poor genetic match for ancestry groups in whom other reduced-function alleles predominate. We close by discussing implementation barriers, point-of-care testing, cost-effectiveness, and the unresolved need for expanded, ancestry-inclusive genotyping panels as the field's clearest open research priority.